1-3 of 3
Andrew Sandler, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Sumithra Vasu, MDMBBS, Nelli Bejanyan, MD, Steven M Devine, MD, Elizabeth O. Hexner, MD MSTR, Brent Logan, PhD, Leo Luznik, MD, Brittany K. Ragon, MD, Andrew Sandler, MD, Elizabeth F Krakow, MDMSc, Michael Fitzgerald, Lorraine Tracey, PhD, Richard E. Champlin, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-134408
Published: 2020
Journal Articles

Head-to-Head Comparison of Haploidentical HSCT Strategies for Hematologic Malignancies: Phase III Hatcy Study of T-Cell-Depleted HSCT with Adjunctive ATIR101 Versus T-Cell-Replete HSCT with Post‐Transplant Cyclophosphamide

Denis Claude Roy, MD, Bernd-Jan Sanson, Jonas Hylton, PharmD, Andrew Sandler, MD, Stephan Mielke, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4464.
https://doi.org/10.1182/blood-2019-125592
Published: 2019
Journal Articles

Depletion of Alloreactive T Cells after Haploidentical HSCT: Comparison of Outcomes for Ex Vivo Versus In Vivo Treatment Strategies

Steven Devine, Stephan Mielke, MD, Eduardo Olavarria, Bert Tuk, Kees Meewisse, Andrew Sandler, MD, Denis-Claude Roy, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3474.
https://doi.org/10.1182/blood-2018-99-118857
Published: 2018